45 results about "Serogroup c" patented technology

A composition comprising (a) Neisseria meningitidis serogroup B outer membrane vesicles (OMVs), and (b) an immunogenic component selected from other Neisseria proteins, or immunogenic fragments thereof. Component (b) preferably includes a protein from a different NmB strain from that from which the OMV of component (a) is derived. The OMVs are preferably obtained by deoxycholate extraction. Optionally, the composition may also comprise a protective antigen against other pathogens.

The invention provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of N. meningitidis. It is preferred that the capsular saccharides in the compositions of the invention are conjugated to carrier protein(s) and / or are oligosaccharides. Conjugated oligosaccharide antigens are particularly preferred. The invention also provides immunogenic compositions comprising (a) a capsular saccharide antigen from serogroup C of N. meningitidis, and (b) a chitosan adjuvant. The composition preferably comprises (c) one or more further antigens and / or (d) one or more further adjuvants. The compositions are particularly suitable for mucosal delivery, including intranasal delivery. The use of chitosan and / or detoxified ADP-ribosylating toxin adjuvants enhances anti-meningococcal mucosal immune responses and can shift the Th1 / Th2 bias of the responses.

In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.

The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.check for moving around

The invention provides vaccines against Neisseria meningitidis, pneumococcus and DTPa / w. In particular, it provides vaccines based on conjugated capsular saccharides from multiple meningococcal and / or pneumococcal serogroups. It further provides vaccine administration schemes for the immunisation of human patients with two or more of these vaccines.

The present invention describes derivatized polysaccharide-protein conjugates, a composition comprising one or more of such derivatized polysaccharide-protein conjugates and methods of immunizing human patients with the same. The derivatized polysaccharide-protein conjugates are purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y, derivatized chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains.

Provided are recombinant DNA molecules that do not occur in nature encoding an O-acetyltransferase, vectors that direct expression of an O-acetyltransferase, recombinant host cells which express an O-acetyltransferase, methods for recombinant production of an O-acetyltransferase, methods for acetylating capsular polysaccharides, especially those of a Serogroup A Neisseria meningitidis using a recombinant O-acetyltransferase, and immunogenic compositions comprising the acetylated capsular polysaccharide.

Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular B. pertussis antigen; (b) co-administration with an inactivated poliovirus antigen; (c) supply in a kit together with a separate pneumococcal conjugate component, which may be in a liquid form; and (d) use in combination with a pneumococcal conjugate antigen but without an aluminum phosphate adjuvant. A kit may have: (a) a first immunogenic component that comprises an aqueous formulation of a conjugated capsular saccharide from Streptococcus pneumoniae; (b) a second immunogenic component that comprises a conjugated capsular saccharide from Neisseria meningitidis serogroup C.

In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular B. pertussis antigen; (b) co-administration with an inactivated poliovirus antigen; (c) supply in a kit together with a separate pneumococcal conjugate component, which may be in a liquid form; and (d) use in combination with a pneumococcal conjugate antigen but without an aluminium phosphate adjuvant. A kit may have: (a) a first immunogenic component that comprises an aqueous formulation of a conjugated capsular saccharide from Streptococcus pneumoniae; (b) a second immunogenic component that comprises a conjugated capsular saccharide from Neisseria meningitidis serogroup C.

The invention provides immunogenic compositions comprising (a) a capsular saccharide antigen from serogroup C of N. meningitidis, and (b) a chitosan adjuvant. The composition preferably comprises (c) one or more further antigens and / or (d) one or more further adjuvants. The compositions are particularly suitable for mucosal delivery, including intranasal delivery. The invention also provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of N. meningitidis. It is preferred that the capsular saccharides in the compositions of the invention are conjugated to carrier protein(s) and / or are oligosaccharides. Conjugated oligosaccharide antigens are particularly preferred.

Combination vaccines for treating or preventing Neisseria meningitidis infection are described. The vaccines include Neisseria meningitidis serogroup B proteoliposomic vesicles and Neissera meningitidis serogroup C conjugated oligosaccharides.

In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

The invention is based on methods that allow analysis of mixed meningococcal saccharides from multiple serogroups even though they share monosaccharide units. With a combination of saccharides from serogroups C, W135 and Y, the invention analyses sialic acid, glucose and galactose content. The glucose and galactose results are used to directly quantify saccharides from serogroups Y and W135, respectively, and the combined glucose and galactose content is subtracted from the sialic acid content to quantify saccharides from serogroup C. The three serogroups can thus be resolved even though their monosaccharide contents overlap. The three different monosaccharide analyses can be performed on the same material, without interference between the monosaccharides and without interference from any other saccharide materials in the composition (e.g. lyophilisation stabilisers). The method can be used to analyse total and free saccharide in conjugate vaccines and simplifies quality control of vaccines containing capsular saccharides from multiple serogroups.

International patent application WO99 / 61053 discloses immunogenic compositions that comprise N. meningitidis serogroup C oligosaccharide conjugated to a carrier, in combination with N. meningitidis serogroup B outer membrane protein. These are disclosed in the present application in combination with further Neisserial proteins and / or protective antigens against other pathogenic organisms (e.g. Haemophilus influenzae, DTP, HBV, etc.).

Serogroup B meningococcus antigens can successfully be combined with diphtheria, tetanus and pertussis toxoids (“DTP”) to provide effective combination vaccines for protecting against multiple pathogens. These combinations are effective with a range of different adjuvants, and with both pediatric-type and booster-type DTP ratios. The adjuvant can improve the immune response which the composition elicits; alternatively, by including an adjuvant it is possible for the compositions to have a relatively lower amount of antigen while nevertheless having immunogenicity which is comparable to unadjuvanted combination vaccines.

An 85 kDa antigen from Neisseria meningitidis and Neisseria gonorrhoeae has been cloned, sequenced and expressed. The antigen is common to diverse strains, serogroups and serotypes of N. meningitidis, and also to N. gonorrhoeae, N. polysaccharia and N. lactamica. The protein sequences of N. meningitidis (serogroups A and B) and N. gonorrhoeae are highly homologous.

Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and / or (ii) selecting a fHBP and adjuvant with an isoelectric point / PZC within the range of 5.0 to 7, and / or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant.

The invention relates to real-time fluorescent quantitative RT-PCR detection primers for a serotype of a Palyam serogroup virus (PALV), probes and a detection kit and belongs to the technical field ofmolecular biological detection on animal viruses. The kit comprises 3 pairs of primers and further comprises three probes, a negative control template, positive control templates, standard substancetemplates and a PCR amplification reagent. RNase-free water serves as the negative control template; the positive control templates are CHUV, BCV and DAV inactivated viruses separately; and the standard substance templates are gene segment 2 single-stranded RNAs of CHUV, BCV and DAV. The kit disclosed by the invention can be used for detecting three kinds of serotype PALVs popular in China and hasthe advantages of specificity, sensitivity, rapidness, high efficiency and the like; and a standard curve established by utilizing the standard substance templates in a matched manner can be used forcarrying out quantitative detection on RNAs of all PALV serotype strains in clinical samples, and thus, the working efficiency is increased greatly.

Novel bactericidal antibodies against Neisseria meningitidis serogroup B (“MenB”) are disclosed. The antibodies either do not cross-react or minimally cross-react with host tissue polysialic acid and hence pose minimal risk of autoimmune activity. The antibodies are used to identify molecular mimetics of unique epitopes found on MenB or E. coli K1. Examples of such peptide mimetics are described that elicit serum antibody capable of activating complement-mediated bacteriolysis of MenB. Vaccine compositions containing such mimetics can be used to prevent MenB or E. coli K1 disease without the risk of evoking autoantibody.

The present invention relates to synthesis of novel higher oligomers and process of preparing the same. In particular the present invention relates to the chemical synthesis of oligomers of Neisseria meningitidis serogroup X (‘hereinafter Men-X), more particularly tetramer. The present invention provides Men-X capsular oligomers obtained from synthetic pathway using purified saccharides of specific chain length and provides said novel oligomers as candidates for the development of conjugate vaccine against bacterial meningitis caused due to Men-X infections.

A vaccine including outer membrane vesicles from Neisseria meningitidis serogroup A may be used to protect humans against disease caused by meningococci of serogroup A. A process for producing such outer membrane vesicles is also disclosed.

The invention provides immunogenic compositions comprising (a) a capsular saccharide antigen from serogroup C of N. meningitidis, and (b) a chitosan adjuvant. The composition preferably comprises (c) one or more further antigens and / or (d) one or more further adjuvants. The compositions are particularly suitable for mucosal delivery, including intranasal delivery. The invention also provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of N. meningitidis. It is preferred that the capsular saccharides in the compositions of the invention are conjugated to carrier protein(s) and / or are oligosaccharides. Conjugated oligosaccharide antigens are particularly preferred.

Analysis of compositions that include saccharides having mannosamine residues, such as the capsular saccharide of N. meningitidis serogroup A, is facilitated by a method comprising the steps of: (i) hydrolysing polysaccharide in the sample, to give a hydrolysate; (ii) subjecting the hydrolysate to liquid chromatography; and (iii) detecting any mannosamine-6-phosphate separated in step (ii).

An antigen composition for stimulating an immune response in an inoculated avian species to at least one intestinal pathogenic organism includes naturally-occurring wild Salmonella enterica subspecies in O-serogroups B, C3 and D. Subspecies in O-serogroup B can include Salmonella typhimurium and / or Salmonella agona. Subspecies in O-serogroup C3 can include Salmonella Kentucky. Subspecies in O-serogroup D can include Salmonella enteritidis. The antigen composition can be used alone or in combination with a Marek's Disease vaccine to reduce shedding of E. coli and / or Salmonella bacteria.

The invention relates to a real-time fluorescent quantitative RT-PCR detection primers, probe and kit for Palyamserogroup virus, and belongs to the technical field of animal virus molecular biologicaldetection. The kit comprises an upstream primer, a downstream primer, the probe matched with the primers for use, a negative control template, a positive control template, a standard template and a PCR amplification reagent. The kit is adopted for detection, the reaction speed is high, and the whole amplification process is less than 1 hour; only virus RNA needs to be extracted, reverse transcription is not needed, operation steps are few, easy and convenient, and RNA degradation and pollution can be effectively avoided; meanwhile, after qRT-PCR amplification is completed, whether PALV RNA exists in a sample to be detected or not can be directly judged without agarose gel electrophoresis; and in addition, a standard curve established with the help of the standard template can be used forquantitatively detecting the PALV RNA in the clinical sample, so that the working efficiency is greatly improved, and the detection cost is reduced.

This disclosure relates to vaccine formulations comprising an immunogenic composition for inducing antibodies to both S. pneumoniae and N. meningitides in a subject. In a preferred aspect, the immunogenic composition comprises covalently conjugated recombinant PsaA (“rPsaA”) from S. pneumoniae and capsular polysaccharide from N. meningitidis serogroup C. This disclosure further relates to methods for producing the immunogenic composition as well as methods for their use.

The present invention discloses a rapid high yielding purification process for Neisseria meningitidis serogroup X capsular polysaccharide. The capsular polysaccharide of present invention is capable of being used in the production of economical monovalent capsular polysaccharide or polysaccharide protein conjugate vaccine or multivalent combination vaccines as well as a diagnostic tool against meningococcal serogroup X infections. The process employs simple salts and lesser quantity of ethanol. The process is rapid, economic and scalable with high yield of purified polysaccharide of Neisseriameningitidis serogroup X.

An 85kDa antigen from Neisseria meningitidis and Neisseria gonorrhoeae has been cloned, sequenced and expressed. The antigen is common to diverse strains, serogroups and serotypes of N. meningitidis, and also to N. gonorrhoeae, N. polysaccharia and N. lactamica. The protein sequences of N. meningitidis (serogroups A and B) and N. gonorrhoeae are highly homologous.